
Interim Results of the US Fenfluramine Oral Solution Cardiovascular Safety Registry Study

Introduction

- In the United States (US), fenfluramine (FFA oral solution, FINTEPLA[®]) is FDA-approved for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients ≥ 2 years old¹
- Due to cardiovascular (CV) risks, namely valvular heart disease (VHD) and pulmonary arterial hypertension (PAH), originally identified when in the past the FFA oral tablet formulation was used at high doses as an anorectic agent (at 60-120 mg/day), FINTEPLA[®] is only available in the US through a Risk Evaluation and Mitigation Strategy (REMS)¹
- Starting dose is 0.1 mg/kg twice daily (0.2 mg/kg/day), increased weekly based on efficacy and tolerability up to 0.35 mg/kg twice daily (0.7 mg/kg/day) or 0.2 mg/kg/day twice daily (0.4 mg/kg/day) if on concomitant stiripentol (STP)
- Doses not to exceed 26 mg/day or 17 mg/day if on concomitant STP
- Prescribers and dispensing pharmacies must be certified through REMS and patients must also be enrolled in REMS to receive the medication
- To evaluate for VHD and/or PAH, a baseline echocardiogram (ECHO) must be obtained before starting treatment with FINTEPLA[®] and a repeat ECHO is then needed every 6 months and once 3-6 months after stopping FINTEPLA®
- The FDA has required a post-marketing CV safety registry study in the US, including all patients who enrolled in the FINTEPLA® REMS, to continue monitoring, evaluating, and reporting VHD, PAH, and/or other CV adverse events (CVAEs); the study includes data obtained from REMS, pharmacovigilance processes, and clinical studies/expanded access programs (**Figure 1**)
- In a large prospective cohort of middle-aged patients with epilepsy, VHD, hypertension, coronary artery disease, heart failure, and congenital heart disease were more prevalent in patients with epilepsy versus comparators without epilepsy $(P < 0.001)^2$
- As with all patients with epilepsy, CV events in patients with DS or LGS may be due to various factors
- These include underlying cardiac conditions, comorbidities, use of antiseizure medications, and chronic seizures causing structural, electrical and/or mechanical dysfunction³⁻⁵

Figure 1. Components of the FINTEPLA® CV Safety Registry Study



CV, cardiovascular; REMS, Risk Evaluation and Mitigation Strategy.

Objective

To provide interim results from the CV safety registry study, since launch of FINTEPLA® (June 2020), whose objective is to characterize the risk of potential development of VHD and/or PAH (**Figure 2**) in patients exposed to FINTEPLA[®] in the US.

Figure 2. Overview of Definitions

$\left[\right]$	REMS-defined VHD (agreed with FDA)
	 Mild or greater aortic regurgitation or moderate or greater mitral regurgitation associated with restricted valve motion, valve thickening, and/or physical signs or symptoms attributable to valve disease
	REMS-defined PAH (agreed with FDA)

FDA, Food and Drug Administration; PAH, pulmonary arterial hypertension; REMS, Risk Evaluation and Mitigation Strategy; VHD, valvular heart disease.

Methods

- patients treated with FINTEPLA® in the US
- (Figure 1)

 - Data are collected from REMS enrollment (pre-treatment baseline), through followup during FINTEPLA[®] treatment, at study end, or when patients are lost to follow-up
 - During FINTEPLA[®] treatment, data are collected via REMS every 6 months and 3-6 months after the last FINTEPLA® dose
- If information from any source suggests REMS criteria of VHD or PAH are met, the cases are included in the analysis
- Cases of suspected VHD or PAH are reviewed by an external adjudication committee to support the correct diagnosis of the event
 - The committee consists of three cardiologists with expertise in adult and pediatric cardiology and knowledge of FINTEPLA®
 - The adjudication committee reviews all medical information reported for the cases (including but not limited to ECHO imaging and results, clinical course, comedication, and comorbidities) and makes a clinical judgment to classify them as definite, probable, possible, or not VHD/PAH
- Data collection period for this interim report was June 25, 2020, through June 24, 2024

Table 1. Overview of Data Collection Sources and Types of Data Collected

	Data Collection Source	Data Source/ Reporter(s)	Timing of Completion	Data Collected
	REMS patient enrollment form	Patient or caregiver <u>and</u> prescriber	Enrollment	Registration informationDemographics
REMS forms	REMS patient status form	Prescriber	 Before start of FINTEPLA[®] Every 6 months during FINTEPLA[®] treatment 3-6 months after final FINTEPLA[®] dose 	 Height, weight FINTEPLA[®] exposure information^a ECHO results
	REMS CVAE reporting form	Prescriber	 At or immediately after CVAE reported 	 CVAE information FINTEPLA[®] exposure information^a (including STP use)
Pharmacovigilance targeted follow-up form		Prescriber and/or other healthcare provider involved in the integrative care of the patient	 After CVAE reported or when CVAE form is received 	 Information re: CVAE^b Other exposure information^c Medical comorbidities Concomitant medications Family history
<i>Clinical studies or expanded access programs</i>		Patient or caregiver and prescriber	• Enrollment	Pre-REMS exposure

aIncludes start/end date of FINTEPLA®, and whether FINTEPLA® was continued or not and reasons for discontinuation if applicable. ^bIncludes whether the CVAE was reviewed by a patient's cardiologist, if a VHD/PAH diagnosis was made, as well as other information that may assist in evaluating the events. ^cIncludes medical history, concomitant medications, recreational drug exposure, and laboratory test results. CVAE, cardiovascular adverse event; ECHO, echocardiogram; REMS, Risk Evaluation and Mitigation Strategy; STP, stiripentol.

• The CV safety registry study is an ongoing prospective, observational, cohort study of

• Data are collected from REMS, pharmacovigilance processes, and clinical studies/expanded access programs from patients enrolled in the FINTEPLA® REMS

An overview of the data collection process is provided in Table 1

Outcomes

- Variables and outcomes reported included: patient demographics, FINTEPLA[®] mean daily dose, duration of FINTEPLA[®] exposure, occurrence of potential symptomatic or asymptomatic VHD and/or PAH (regardless of FINTEPLA® causality), and results of definite or probable cases following adjudication review
 - As noted above, suspected cases undergo additional follow-ups and adjudication for confirmation of diagnosis
 - Causality criteria for potential cases of VHD and/or PAH were also applied by UCB as per World Health Organization-Uppsala Monitoring Centre (WHO-UMC) and are described in this report
 - Considers clinical-pharmacological aspects of the case history and the quality of documentation to categorize as certain, probable/likely, possibly, unlikely, and unassessable

Statistical analyses

 Descriptive statistics were used; specifically, percentages, means, standard deviations, and medians with minimum and maximum values

Results

- Over the data collection period (June 25, 2020, through June 24, 2024), 3563 patients have been enrolled in the REMS and received ≥ 1 dose of FINTEPLA[®] (Enrolled Set)
- Of 3563, 216 (6.1%) patients had an abnormality on baseline ECHO Some of these included: FDA-defined mild and moderate aortic valvulopathy,
- FDA-defined moderate mitral valvulopathy, and REMS-defined PAH • Patient demographics are described in **Table 2**
- Of the enrolled set, mean ± SD FINTEPLA[®] daily dose was 0.5±0.3 mg/kg/day or 17.6±9.3 mg/day
- Total duration of FINTEPLA[®] exposure was 5611.4 patient-years (see **Table 3**)

Table 2. Patient Demographics

	Enrolled Set N=3563	E١
Age, years Mean±SD Range	14.9±10.8 0.1-70.1	
Gender, n (%) Male Female Missing	1883 (52.8) 1678 (47.1) 2 (0.1)	
Weight at enrollment (kg) n Mean±SD	3554 43.3±25.5	
BMI at enrollment (kg/m²) n Mean±SD	3115 21.3±6.6	

BMI, body mass index; CV, cardiovascular; SD, standard deviation.

Table 3. Duration of FINTEPLA® Exposure

Patients initiating FINTEPLA® *prior* to REMS enrollment, patient-years Pre-REMS duration of exposure^a REMS duration of exposure

Patients initiating FINTEPLA® from REMS enrollment, patient-years


Total duration of exposure, patient-years

Total

^aIncludes FINTEPLA[®] exposure from participation in clinical trials or expanded access programs. REMS, Risk Evaluation and Mitigation Strategy.

Almasa Bass, PharmD¹; Diego Morita, MD¹; Julie Shepherd-Smith, BPharm²; Rebecca Zhang Roper, MD, PhD²; Aleksey Gitelson, PharmD¹; Evi Tselenti²; Amélie Lothe, PhD³; Jenna Roberts, PhD²; Namita Nayak¹





- Of the reports of REMS-defined PAH cases:
 - \circ 3 were adjudicated as definite (n=2) or probable (n=1) PAH; all were likely caused by pre-existing cardiac abnormalities and concurrent respiratory infections and, thus, unlikely related to FINTEPLA®



 No patient had both REMS-defined VHD and REMS-defined PAH and no patient experienced symptomatic VHD or PAH

• There was no change to FINTEPLA[®] treatment in 14/18 patients; in the 4 remaining patients (2 REMS-defined VHD and 2 REMS-defined PAH), FINTEPLA[®] was discontinued • One additional case that did not meet the REMS definition of PAH (pulmonary arterial systolic pressure = 35 mmHg) was adjudicated as a probable PAH based on information

• This patient was likely developing PAH which appeared to resolve after discontinuation of FINTEPLA[®]; this case was not associated with any confounding factors and likely related to FINTEPLA®

Conclusions

• As of data cutoff date and approximately 4 years of evaluation for this interim report, 3563 patients have been enrolled in the FINTEPLA[®] REMS representing 5611 patient-years of FINTEPLA[®] exposure in the US

• The adjudication committee classified 2 cases (0.06%) as definite or probable VHD and 3 cases (0.08%) as definite or probable PAH, with one patient not having additional confounding factors; thus, only one case possibly related to FINTEPLA®

 No cases of symptomatic VHD or PAH were reported and regular ECHO monitoring enabled early identification of CV events

• Results of this interim report add to the current understanding of the CV safety profile of FINTEPLA® and help to inform patients, caregivers, and healthcare providers of the incidence of CVAEs

• The benefit-risk balance is favorable for patients with DS or LGS

• Timely reporting of AEs with high quality information from healthcare providers is important for assessing the safety profile of medications

• Ongoing treatment in any patient, including the decision to continue or discontinue FINTEPLA[®], involves the benefit-risk assessment by the healthcare provider in consultation with patient and caregiver

References

1. UCB, Inc. FINTEPLA® (fenfluramine) oral solution [prescribing information]. Smyrna, GA; March 2023. 2. Shah RA, et al. *Can J Cardiol.* 2024;40(4):688-95.

3. Verrier RL, et al. *Epilepsy Behav.* 2020;105:106946.

4. Verrier RL, Schachter SC. *Epilepsy Behav Rep.* 2024;27:100696.

5. Surges R, et al. *Epileptic Disord.* 2021;23(1):17-39.

Acknowledgements

UCB Pharma-sponsored. The authors acknowledge Tom Grant, PhD (UCB Pharma, Slough, UK), for managing the development of the poster, and Sandra M Aguero, PharmD, BCPS, and Scott Bergfeld, PhD, of PharmaWrite, LLC (Princeton, NJ, USA), for writing and editorial assistance, which was funded by

Disclosures

All authors are employees of UCB with stock ownership.

For a copy of this poster, use your smartphone to scan the QR code, download from the website below, or contact UCB**Cares**®

Website: UCBposters.com/AES2024; Poster ID: AES2024-1.501 Phone: +1-844-599-CARE (2273)

mail: UCBCares@ucb.com

American Epilepsy Society 78th Annual Meeting Los Angeles, CA, USA | December 6–10, 2024